Levels of endothelial cell-specific molecule-1 (ESM-1) in overt hypothyroidisim

Güngör, Âdem; Palabıyık, Şaziye Sezin; Bayraktutan, Zafer; Dursun, Hakan; Gokkaya, Naile; Bilen, Arzu; Bilen, Habib

doi:10.3109/07435800.2015.1135443

Cited by 10 publications

(8 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In other diseases with vascular impact, such as hypothyroidism, 141,142 CAD, 15,143 –145 hypertension, 15,146 diabetes mellitus, 147,148 chronic kidney disease, 149 and obstructive sleep apnea, 150 endocan levels were also evaluated to understand their relation with the CV risk of each disease. Endocan levels are significantly elevated in these diseases and were found to reflect ED, as they were correlated with the disease severity and with both FMD and cIMT.…”

Section: Endocanmentioning

confidence: 99%

Novel Biomarkers for Evaluation of Endothelial Dysfunction

et al. 2020

View full text Add to dashboard Cite

Endothelial dysfunction is one of the earliest indicators of cardiovascular (CV) dysfunction, and its evaluation would be of considerable importance to stratify CV risk of many diseases and to assess the efficacy of atheroprotective treatments. Flow-mediated dilation is the most widely used method to study endothelial function. However, it is operator-dependent and can be influenced by physiological variations. Circulating biomarkers are a promising alternative. Due to the complexity of endothelial function, many of the biomarkers studied do not provide consistent information about the endothelium when measured alone. New circulating markers are being explored and some of them are thought to be suitable for the clinical setting. In this review, we focus on novel biomarkers of endothelial dysfunction, particularly endothelial microparticles, endocan, and endoglin, and discuss whether they fulfill the criteria to be applied in clinical practice.

show abstract

Section: Endocanmentioning

confidence: 99%

Novel Biomarkers for Evaluation of Endothelial Dysfunction

et al. 2020

View full text Add to dashboard Cite

show abstract

“…To date, opinions have been advocated indicating that endocan can be used as a marker in inflammatory diseases. In studies carried out by Arpacı (22) and Güngör (23), it has been revealed that endocan elevation occurring as a result of endothelial dysfunction due to hypothyroidism, can be used as an early marker for cardiovascular diseases. In an article where Voiosu et al compared patients with inflammatory bowel disease (IBD) with a healthy control group and stage 4 cancer patients, endocan levels were found to be significantly higher in patients in the IBD group than in the healthy control group and cancer patients.…”

Section: Discussionmentioning

confidence: 99%

Serum Endocan Levels Can Predict Malignancy Of Thyroid: A Prospective Clinical Study

Şahin

Saydam

Yılmaz

et al. 2020

Anadolu Güncel Tıp Dergisi

View full text Add to dashboard Cite

Aim: The differential diagnosis of benign and malignant diseases of the thyroid is important in borderline malignancies and malignancies that have not been diagnosed with biopsy. This study aimed to determine endocan molecule levels in patients with thyroid cancer, nodular goiter and thyroiditis. Thus, it was aimed to determine the availability of the endocan molecule in the differential diagnosis of thyroid diseases. Material and Method: The study was conducted between March 1, 2018 and August 1, 2018. During this period, patients who were scheduled for surgery due to thyroid disease and wanted to participate in the study voluntarily were included in the study. A prospective, cross-sectional clinical trial was designed. Patients included in the study were divided into four groups, according to their pathology report results; Group 1: Papillary thyroid cancer (PTC), Group 2: Multinodular goiter on thyroiditis background, Group 3: Multinodular goiter (MNG), Group 4: Follicular thyroid cancer (FTC). Results: A total of 72 patients were included in the study. Multiple analysis comparing the four groups, showed no statistically significant difference between the groups (p>0.050). When the benign and malignant patient groups were compared, endocan levels were found to be statistically significantly higher in the malignant group (p=0.0375). When thyroid carcinoma groups were compared among themselves, the endocan level was detected to be higher in FTC, compared to PTC (p=0.047). Conclusion: The level of "endocan" was observed to increase in malignant thyroid diseases. This was particularly so in FTC, which shows spreading via the hematogenous route. This is an encouraging sign that the "endocan" molecule can be used as a general tumor marker. However, prospective additional studies with large randomized series are needed.

show abstract

“…In addition to all the other mechanisms, endocan and U-II are associated with the endocrine system, insulin resistance, obesity and diabetes mellitus. The high comorbidity of metabolic disease and BAD may indicate a common effect 18,19,62–64)…”

Section: Discussionmentioning

confidence: 99%

“…There is increasing suggestion in the literature that serum endocan levels can be used as an early biological marker of endothelial injury, as well as of its probable significance in determining arteriosclerosis and asymptomatic cardiovascular changes in the early stages 15–17). In addition, higher endocan levels have been linked to insulin resistance and hypothyroidism 18,19)…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Endothelial Dysfunction in Bipolar Affective Disorders: Serum Endocan and Urotensin-II Levels

Oral

Halıcı

Çınar

et al. 2019

Clin Psychopharmacol Neurosci

View full text Add to dashboard Cite

Objective This study investigated changes in urotensin-II (U-II) and endocan levels which can be used as an early biological marker of endothelial injury in the episode and remission phases of bipolar affective disorder (BAD). Methods We compared endocan and U-II levels, which has been shown to be closely associated with neurotransmitter systems in addition to continuity of endothelial structure and inflammatory response, in patients with BAD in remission for at least one year (n=42) and in patients still in manic or depressive episodes (n=16) with healthy controls (n=30). Results Both endocan and U-II levels were significantly higher in the bipolar patients than in the controls. Endocan and U-II levels were also significantly correlated with one another ( p =0.000, r=0.833). Both endocan ( p =0.000) and U-II levels ( p =0.000) were significantly higher in the bipolar attack group compared to the subjects in remission, and in the remission group compared to the controls. Conclusion In this study we determined significantly higher endocan and U-II levels in BAD compared to the controls, while serum endocan and U-II levels of patients undergoing attacks were also significantly higher than those of the controls and also those of patients in remission.

show abstract

Levels of endothelial cell-specific molecule-1 (ESM-1) in overt hypothyroidisim

Cited by 10 publications

References 20 publications

Novel Biomarkers for Evaluation of Endothelial Dysfunction

Novel Biomarkers for Evaluation of Endothelial Dysfunction

Serum Endocan Levels Can Predict Malignancy Of Thyroid: A Prospective Clinical Study

Evaluation of Endothelial Dysfunction in Bipolar Affective Disorders: Serum Endocan and Urotensin-II Levels

Contact Info

Product

Resources

About